Figure 2
Figure 2. Incorporation of EPC-derived MVs in HMECs. (A) Representative FACS analysis of internalization, after a 30-minute incubation at 37°C, by HMECs of MVs labeled with PKH26 (filled curve). HMECs were incubated with vehicle alone as internal control (open curve). (B-F) Representative FACS analysis of internalization of MVs preincubated (open curves) or not (filled curves) with 1 μg/mL blocking mAb against ICAM-1 (B), with 5 μg/mL soluble Ha (C), 1 μg/mL blocking mAb against α6 integrin (D), α4 integrin (E), CD29 (F). Filled curves indicate the MVs internalized in the absence of blocking Abs or Ha; open curves indicate the MVs internalized after incubation with blocking Abs or soluble Ha. Three experiments were performed with similar results.

Incorporation of EPC-derived MVs in HMECs. (A) Representative FACS analysis of internalization, after a 30-minute incubation at 37°C, by HMECs of MVs labeled with PKH26 (filled curve). HMECs were incubated with vehicle alone as internal control (open curve). (B-F) Representative FACS analysis of internalization of MVs preincubated (open curves) or not (filled curves) with 1 μg/mL blocking mAb against ICAM-1 (B), with 5 μg/mL soluble Ha (C), 1 μg/mL blocking mAb against α6 integrin (D), α4 integrin (E), CD29 (F). Filled curves indicate the MVs internalized in the absence of blocking Abs or Ha; open curves indicate the MVs internalized after incubation with blocking Abs or soluble Ha. Three experiments were performed with similar results.

Close Modal

or Create an Account

Close Modal
Close Modal